SunRISe-4: TAR-200 plus cetrelimab or cetrelimab alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant platinum-based chemotherapy
Psutka, Sarah P., Cutie, Christopher, Bhanvadia, Sumeet Kaur, Keegan, Kirk A., Crist, Wendy, Tian, Shaozhou Ken, Maffeo, John, Raybold, Bradley, Kashmer, Marietta, Hasan, Mohamad, Li, Xiang, Beeharry, Neil, Thomas, Shibu, Tian, Hui, Powles, Thomas
Published in Journal of clinical oncology (20.02.2023)
Published in Journal of clinical oncology (20.02.2023)
Get full text
Journal Article